Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
|
|
- Octavia Doyle
- 6 years ago
- Views:
Transcription
1 Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received June 5, 2006; accepted August 13, 2006; published online October 23, 2006 Background: This study was performed to determine the characteristics and the clinical outcomes of patients with cutaneous melanoma in Turkey. Methods: The medical records of patients between 1991 and 2003 at Institute of Oncology were retrieved from the cancer registry. Results: Of the 475 adult cases with complete staging procedure, the incidence of localized (stages I II) disease was 301 (63.4%), and followed by node involved (stage III) and metastatic (stage IV) disease with the incidence of 117 (24.6%) and 57 (12.0%), respectively. The median age of patients was 50 years ( years) and male/female ratio was 1.1. Of 206 patients (43.4%) the diseases were located on extremities, 150 (31.6%) on the trunk, and 102 (21.5%) on the head and neck region. In cases with early/node negative stage, stage distribution was identical. The superficial spreading type was the commonest histology (52.2%). The Breslow thickness distributed equally, whereas tumor invasion aggregated mainly at Clark level III and IV. Half of the lesions were ulcerated and with low mitotic potential. In cases with the node involved stage, the majority of patients had only one lymph node involved. In metastatic patients, two thirds had distant metastases including lung metastases and half of them had single metastatic region. With the median follow-up of all patients of 5.2 years, the median overall survival of all patients was 62.2 months and the 5-year overall survival was 50.5%. Overall survival was significantly negatively correlated with male (P, 0.001), advanced stages (P, 0.001) and old ages (P ¼ 0.005). The five-year survival rates of patients with stages I II and III disease were 63.6% and 36.6%, respectively. Nodular histology subtype, deeper Breslow tumor depth, extensive invasion, presence of ulceration, advanced stage, presence of relapse, being male and elderly patient, presence of visceral recurrence, and high mitotic activity were found to be associated with poor prognosis for overall survival in localized disease. The median survival of metastatic patients was 9.9 months and 1-year overall survival rate was 32.7%. Unresponsiveness to chemotherapy, visceral metastasis, multiple metastases and not given chemotherapy were the poor prognostic factors for overall survival. Conclusion: The descriptive and prognostic factors in Turkey are similar to those in Western countries. Key words: melanoma prognostic factor Turkey Jpn J Clin Oncol 2006;36(12) doi: /jjco/hyl114 INTRODUCTION Recently, melanoma has become a major health problem in many countries. The incidence rate of melanoma is increasing worldwide much more rapidly than any other human malignancies. The life time risk of melanoma is 1:70 in For reprints and all correspondence: Faruk Tas, Istanbul Universitesi, Onkoloji Enstitusu, Capa 34390, Istanbul, Turkey. faruktas2002@ yahoo.com the population of the USA and will probably be 1:50 in 2010 (1). Like any other malignancies, melanoma has the potential of metastasizing through lymph nodes to visceral organs. Survival of patients with melanoma is strongly associated with tumor stage at presentation. Therefore, the 5-year survival rates are 68 93% in stages I II, 45 49% in stage III, and 11 18% in stage IV disease (2 4). The strongest prognostic factors are the tumor thickness and ulceration in stages I II, number of lymph node # 2006 Foundation for Promotion of Cancer Research
2 Jpn J Clin Oncol 2006;36(12) 795 metastases in stage III and anatomic site of metastases in stage IV (3,4). Other crucial prognostic factors are the anatomic localization of lesion, age, gender and racial status. Additional negative prognostic factors include lesions located on the head and neck, and trunk, patient age more than 60 years, male gender and being nonwhite. Also, various histopathologic features including nodular and acral lentiginous subtypes, vertical growth phase, high mitotic activity and presence of microscopic satellites are associated with unfavorable prognosis. No report has been published in Pubmed literature that has examined the features of the Turkish melanoma patients. In order to understand the clinicopathological characteristics of malignant melanoma in Turkey, we studied a large series of cases collected between 1991 and PATIENTS AND METHODS The records of the cases of adult, cutaneous malignant melanoma which have been pathologically proven at the Institute of Oncology, Istanbul University between January 1991 and December 2003 were retrieved from the cancer registry for review of the clinicopathological features and outcome. Staging was determined according to the American Joint Committee on Cancer (AJCC) staging system. In situ melanoma patients were not included in the study. Overall survival was analyzed by the Kaplan Meier method. Overall survival time was calculated from the onset of primary melanoma diagnosis to the date of the last follow-up at which patients were still alive or to the date of death. Univariate analysis of the association between the prognostic factors and survival was performed using log rank. Values of P, 0.05 were considered to be significant. RESULTS DISTRIBUTION Four hundred and seventy-five adult cases of cutaneous malignant melanoma were recorded in the cancer registry. All of the patients were Caucasians. All characteristics concerning patients and the disease are shown in Table 1 on a stage basis. Of the 475 cases with complete staging procedure, the incidence of localized (stages I II) disease was 301 (63.4%), followed by node involved (stage III) and metastatic (stage IV) disease with the incidence of 117 (24.6%) and 57 (12.0%), respectively. The age of the 475 patients ranged from 17 to 104 years (median: 50 years). The male to female ratio was 1.1. The diseases were located on extremities (38 acral) in 206 (43.4%) patients, on the trunk in 150 (31.6%) and on the head and neck in 102 (21.5%). In 301 cases with early, node negative stage, stage distribution was equal. The superficial spreading was the Table 1. Patient and disease characteristics Patient group Parameter n % All patients No. of patients Age (median, range) 50 (17 104) þ Gender Male Female Localization Head neck Trunk Extremity Primary unknown Multiple Stage I II Stage IA IB IIA IIB IIC Undetermined Histology Superficial spreading Nodular Acral lentiginous Lentigo maligna Others and undifferentiated Breslow thickness (mm), Clark invasion I II III IV V Ulceration Yes No Mitosis Continued
3 796 Melanoma in Turkey: analysis of 475 cases Table 1. Continued Patient group Parameter n % Tumor infiltrating lymphocyte Absent Present Regression No Yes Interferon treatment (for stage IIb c) No Yes Relapse No Yes Site of recurrence Non-visceral Visceral Stage III Nodal status N N N Application of sentinel node dissection Yes No Interferon treatment No Yes Relapse in patients treated with Interferon No Yes Stage IV M1 stage M1a b M1c Number of metastases Single Multiple Application of chemotherapy Yes No Response to chemotherapy Yes No commonest histology (52.2%). The Breslow thickness of cases presented on equal distribution, whereas tumor invasion aggregated mainly at Clark level III and IV. Half of the lesions were ulcerated and with low mitotic potential. The majority of lesions were infiltrated by tumor lymphocytes and not regressed. The intermediate dose of adjuvant interferon treatment with either IFN alpha 2a, 9 MU or IFN alpha 2b, 10 MU per day, subcutaneously, for 1 year consisted of an induction period (5 days/week for 4 weeks) followed by 48 weeks of the same dose administered three times per week was given to nearly half of the patients with stages IIB and C. During follow-up of the patients, relapses occurred in 68 (22.6%) patients and most of them were non-visceral (61.3%). In 117 patients with node involvement, for the majority (59%), this was only in one lymph node. Sentinel lymph node biopsy was performed in almost half of the patients with clinically node negative lymph node to determine lymph node status (45.8%). The intermediate dose interferon treatment was preformed in 66 (56.4%) patients as adjuvant therapy. In patients (n ¼ 57) with metastatic lesions at presentation, two thirds were with distant metastases including lung metastases. Nearly half of them had single metastasis (54%). Chemotherapy consisting of various single and combination protocols was performed in majority of the patients, including good performance status and patients without brain metastasis (71%). Response to chemotherapy was determined in one-third of the patients (36%). SURVIVAL AND PROGNOSTIC FACTORS OVERALL STAGES The median follow-up of all patients was 62.2 months (range: months). The median overall survival of all patients was 62.2 months (range: months). A 5-year overall survival was % (Fig. 1). There were 146 (30.7%) deaths as a result of disease progression. Overall survival was significantly negatively correlated with male patients (P, 0.001), advanced stages (stages III IV) (P, 0.001) and elderly patients (P ¼ 0.005) (Table 2), but the site of disease did not effect survival (P ¼ 0.57). EARLY STAGES The median overall survival of 301 (63.4%) patients was months (range: months). The 5-year overall survival was % (Figs 2 and 3). There were 66 (21.9%) deaths resulting from disease progression. The nodular histology (P, 0.001), deeper tumor depth (P, 0.001), extensive invasion (P, 0.001), presence of ulceration (P, 0.001), advanced stage (P, 0.001), presence of relapse (P, 0.001), male patients (P ¼ 0.013), being advanced age (P ¼ 0.027), visceral recurrence (P ¼ 0.030) and high mitotic activity (P ¼ 0.038) were found to be poor prognostic factors for overall survival. However, regression status, treatment with interferon, tumor
4 Jpn J Clin Oncol 2006;36(12) 797 Table 2. Prognostic factors for overall survival in melanoma patients Stage status Prognostic factor Poor prognosis P value Figure 1. Overall survival of 475 patients with malignant melanoma. infiltrating lymphocytes and localization of tumor were not effective on survival (Table 2). NODE POSITIVE, STAGE III STAGES The median overall survival of 117 (24.6%) patients was 46.7 months (range: months). The 5-year overall survival was % (Figs 2 and 4). There were 40 (34.2%) deaths resulting from disease progression. Overall survival was significantly negatively correlated with recurrence after interferon use (P, 0.001) and male gender (P ¼ 0.012). In contrast, the parameters such as, age of the patient, the use of adjuvant interferon, status (number) of involved lymph nodes and the site of primary tumor were not found to be significant predictors of prognosis on survival (Table 2). ADVANCED, METASTATIC STAGES The median overall survival of 57 (12.0%) patients was 9.9 months (range: months). The 1-year overall survival was % (Figs 2 and 4). There were 40 (70.2%) deaths as a result of disease progression. The responses to chemotherapy (P ¼ 0.008), visceral metastasis (P ¼ 0.056), multiple metastases (P ¼ 0.057) and treatment with chemotherapy (P ¼ 0.059) were found to be prognostic factors for overall survival. However, age and gender of the patients and site of the primary tumor did not effect survival (Table 2). Early stage (Stage I II) Node (þ) stage (Stage III) Metastatic stage (Stage IV) Overall stages (Stage I IV) Histology Nodular,0.001 Breslow thickness.2mm,0.001 Clark level IV V,0.001 Ulceration Present,0.001 Stage IIB C,0.001 Relapse Present,0.001 Gender Male Age.50 yrs Site of recurrence Visceral Mitosis.10/mm Regression Interferon therapy Tumor infiltrating lymphocyte Localization Relapse after IFN use Present, Gender Male Age 0.29 Adjuvant IFN therapy 0.36 N status 0.67 Localization 0.71 Response to Yes chemotherapy Stage M1c Number of metastases Multiple Chemotherapy usage Yes Age 0.54 Localization 0.61 Gender 0.85 Stage Advanced (stage,0.001 III IV) Gender Male,0.001 Age.50 yrs Localization 0.57 DISCUSSION In order to understand the clinicopathological characteristics of malignant melanoma in Turkey, we studied a large series of cases collected over 13 years. The results of the current analyses showed that histology, tumor thickness, level of invasion, ulceration, stage of the disease, recurrence, gender of the patients and mitotic rate in patients with localized
5 798 Melanoma in Turkey: analysis of 475 cases Figure 2. Survival estimates according to the stage of disease. Figure 3. Overall survivals of the early-stage (I II) melanoma patients. melanomas (stages I II) whereas gender of patients and relapse after interferon treatment in lymph node positive (stage III) patients were the most powerful predictors of overall survival. In metastatic patients (stage IV) these predictors were found to be stage, number of metastases, response to chemotherapy and chemotherapy usage. Considering the whole melanoma patient group (stages I IV), stage, gender and age of patients were the main predictors of overall survival. With the median follow-up of all patients of 5.2 years, the median overall survival of all patients was 62.2 months and 5-year overall survival was 50.5%. Five-year survival rates of patients with stages I II and III disease were 63.6 and 36.6%, respectively. The median survival of metastatic patients was 9.9 months and 1-year overall survival was 32.7%. These survival rates of our patients seem to be slightly worse compared to other Western originated studies. We supposed that these under normal results are explained by the presence of our slightly more advanced-stage diseases and have poorer prognostic factors in compared with other studies. The clinical and pathologic factors predicting the outcome of melanoma patients have been studied for several decades. After many analyses of prognostic factors from both single institutions and multi-institutional experience (5 9), the largest conducted study was published in 2001 (3). The evidencebased results were incorporated into the new and most up-to-date AJCC melanoma staging. In this trial, the AJCC Melanoma Database consisted of a total of melanoma patients, of whom patients (58%) had information available for all of the factors required for the proposed Tumor Node Metastasis (TNM) classification and stage grouping were used. Of the patients included in this analysis, (73%) had at least 5 years of follow-up information. Figure 4. Overall survivals of the advanced-stage (III IV) melanoma patients. In multivariate analysis of patients with localized melanoma, the two most powerful independent characteristics of the melanoma among all the prognostic variables analyzed were tumor thickness and ulceration. Other statistically significant prognostic factors were patient age, localization of the primary melanoma, level of invasion and gender (3). The tumor thickness was the single most powerful prognostic factor in patients with localized melanoma
6 Jpn J Clin Oncol 2006;36(12) 799 (3 5,7,10). The invasion level does not reflect prognosis as accurately as tumor thickness, nevertheless, it does provide additional prognostic value in thin melanomas (3,4,11,12). Ulceration was identified as one of the most important features of melanoma (3 5,9,10,13,14). According to Balch et al. (3), the interpretation of melanoma ulceration is one of the most reproducible of all the major histopathologic features. The age of patient, especially those over 60 years of age, was demonstrated to be an independent prognostic factor possibly because of declining host defense mechanisms associated with advancing age (3,9,10,15). Data were available for 1201 patients with lymph node metastases, a multivariate analysis demonstrated that the number of metastatic nodes, the tumor burden at the time of staging and absence of ulceration of the primary melanoma were most significant (3). Overall, 49% of all patients with nodal metastases survived 5 years. The overall 5-year survival rate of our patients with node positive of 36.6% is poor and possibly does not reflect the number of involved node distribution because of similar ranges (rate of N1 in all stage III patients was 57 and 59% for Balch s and our patients, respectively). The number of metastatic nodes was the most significant prognostic variable of stage III patients (3,16 18). These findings are not consistent with data of our study. For stage IV, the survival rates were measured in months because only a minority of patients live beyond 1 year. The prognostic influence of different distant metastatic sites were analyzed in 1158 patients using various combinations of sites of metastases (3). With 1-year survival rates ranging from 41 to 59% when used to delineate the M categories into three groups such as M1a, M1b, and M1c, the only significant prognostic variable identified in this analysis was the site of distant metastasis, which was consistent with other studies (3,19 22). When we look at demographical patterns of melanoma in general, in the USA and Australia, the gender ratio of melanoma is nearly 1:1. The mean age of melanoma patients is in the early 50s. The anatomic sites that are most common are the back in white males and the extremities in females. Superficial spreading melanoma is the most common type, representing about two-thirds of all white population melanomas (4). Compared with the general literature data from Western countries, we found similar findings concerning demographical parameters for our melanoma patients in Turkey. In conclusion, in Turkey, there has been no published data on malignant melanoma so far. Thus, this is the first report on the subject. Our findings regarding demographical, survival and prognostic factors are in agreement with data from Western countries. References 1. Burton RC, Coates MS, Hersey P, et al. An analysis of a melanoma epidemic. Int J Cancer 1993;55: Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. A summary of cases from the past decade. Cancer 1998;83: Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001;19: Balch CM, Atkins MB, Sober AJ. Cutaneous melanoma. In: DeVita VT, et al. editors. Cancer Principles and Practice of Oncology, 7th edn. Philadelphia: Lippincott Williams & Wilkins 2005; Balch CM, Murad TM, Soong SJ, et al. A multifactorial analysis of melanoma: prognostic histopathologic features comparing Clark s and Breslow s staging methods. Ann Surg 1978;188: Eldh J, Boeryd B, Peterson LE. Prognostic factors in cutaneous malignant melanoma in stage I: a clinical, morphological and multivariate analysis. Cand J Plast Reconstr Surg Hand Surg 1978;12: Van Der Esch EP, Cascinelli N, Preda F, et al. Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer 1981;48: Buttner P, Garbe C, Bertz J, et al. Primary cutaneous melanoma: optimized cutoff points of tumor thickness and importance of Clark s level for prognostic classification. Cancer 1995;75: Averbook BJ, Russo LJ, Mansour EG. A long-term analysis of 620 patients with malignant melanoma at a major referral center. Surgery 1998;124: Balch CM, Soong SJ, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Ann Surg Oncol 2000;7: Prade M, Sancho-Garnier H, Cesarini JP, et al. Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma. Int J Cancer 1980;26: Shaw HM, McCarthy WH, et al. Thin malignant melanomas and recurrence potential. Arch Surg 1987;122: Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980;45: McGovern VJ, Shaw HM, Milton GW, et al. Ulceration and prognosis in cutaneous malignant melanoma. Histopathology 1982;6: Austin PF, Cruse CW, Lyman G, et al. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994;1: Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981;193: Drepper H, Biess, Hofherr B, et al. The prognosis of patients with stage III melanoma. Cancer 1993;71: Cascinelli N, Vaglini M, Nava M, et al. Prognosis of skin melanoma with regional node metastases (stage II). J Surg Oncol 1984;25: Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma: IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983;1: Sirott M, Bajorin D, Wong G, et al. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 1993;72: Barth A, Wanek LA, Mortan DL. Prognostic factors in melanoma patients with distant metastases. J Am Coll Surg 1995;181: Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:
Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationKatsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe
Akita J Med 36 : 45-52, 2009 45 Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe (Received 22 December 2008, Accepted 15 January 2009)
More informationMelanoma of the Skin INTRODUCTION SUMMARY OF CHANGES
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb
More informationMelanoma of the Skin
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44. Skin of upper limb
More informationORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationAJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
More informationClinical and Pathological Features of Cutaneous Malignant Melanoma: A Retrospective Analysis of 124 Japanese Patients
Clinical and Pathological Features of Cutaneous Malignant Melanoma: A Retrospective Analysis of 24 Japanese Patients Yoshie Kuno, Kazuyuki Ishihara, Naoya Yamazaki and Kiyoshi Mukai 2 'Dermatology Division
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationClinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma
ISRN Dermatology Volume 2013, Article ID 586915, 5 pages http://dx.doi.org/10.1155/2013/586915 Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome
More informationAmelanotic melanoma of the skin detailed review of the problem
of the skin detailed review of the problem Strahil Strashilov 1, Veselin Kirov 2, Angel Yordanov 3, Yoana Simeonova 4 and Miroslava Mihailova 5 1. Department of Plastic Restorative, Reconstructive and
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More information1
www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,
More informationPolypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern
Polypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern ELIZABETH A. MANCI, M.D., CHARLES M. BALCH, M.D..TARIQ M. MURAD, M.D., PH.D., AND SENG/JAW SOONG, PH.D. Manci, Elizabeth A., Balch, Charles
More informationQuality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology
More information47. Melanoma of the Skin
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationSpringer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone
Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published
More informationUniversity of Groningen
University of Groningen Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients Faut, Marloes; Wevers, Kevin; van
More informationSentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC
Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC David W. Ollila MD James and Jesse Millis Professor of Surgery University of North Carolina, Chapel Hill Disclosures: None July 15, 2018 AJCC
More informationMeasure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology reports
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationPoor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment
Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment Makenzie L. Hawkins, MSPH 1 Matthew J. Rioth, MD 1,2 Megan M. Eguchi, MPH 1 Myles Cockburn, Phd
More informationWhat are the new AJCC Staging System changes, and how will they affect my patients?
What are the new AJCC Staging System changes, and how will they affect my patients? Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine University of Pennsylvania
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationDisclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION
8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,
More informationSurgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick)
1941 Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick) Long-Term Results of a Large European Multicentric Phase III Study David Khayat, M.D., Ph.D.
More informationTumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed?
Ann Surg Oncol (2015) 22:2978 2987 DOI 10.1245/s10434-014-4349-3 ORIGINAL ARTICLE MELANOMAS Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? A Single-Institution Database
More informationLong-Term Survival Analysis and Clinical Follow-Up in Acral Lentiginous Malignant Melanoma Undergoing Sentinel Lymph Node Biopsy in Korean Patients
Ann Dermatol Vol. 26, No. 2, 2014 http://dx.doi.org/10.5021/ad.2014.26.2.177 ORIGINAL ARTICLE Long-Term Survival Analysis and Clinical Follow-Up in Acral Lentiginous Malignant Melanoma Undergoing Sentinel
More informationLymph node ratio is an important and independent prognostic factor for patients with stage III melanoma.
Thomas Jefferson University Jefferson Digital Commons Department of Surgery Faculty Papers Department of Surgery 1-1-2012 Lymph node ratio is an important and independent prognostic factor for patients
More informationTherapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
Ann Surg Oncol (01) 19:91 91 DOI.14/s44-01-401- ORIGINAL ARTICLE MELANOMAS Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? K. P. Wevers, MD, E. Bastiaannet,
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Melanoma 2013 2014 NAACCR Webinar Series April 3, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationNIH Public Access Author Manuscript J Surg Oncol. Author manuscript; available in PMC 2012 August 1.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Oncol. 2011 August 1; 104(2): 111 115. doi:10.1002/jso.21903. Does metastasectomy improve survival in patients with Stage IV
More informationElevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma
1142 Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma FARUK TAS and KAYHAN ERTURK Department of Medical Oncology,
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationClinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience
2015;23(2):122-129 CLINICAL ARTICLE Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience Damir Homolak 1, Mirna Šitum 2,3, Hrvoje
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationJohan Lyth, J Hansson, C Ingvar, E Mansson-Brahme, P Naredi, U Stierner, G Wagenius and C Lindholm. Linköping University Post Print
Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark s level of invasion: results of a population-based study from the Swedish Melanoma Register Johan
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationMalignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha
Malignant tumors of melanocytes : Part 3 Deba P Sarma, MD., Omaha Let s go over one case of melanoma using the following worksheet. Of the various essential information that needs to be included in the
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationUpdates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD
Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationPrognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma
Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma Otmar Elsaeßer 1., Ulrike Leiter 1 *., Petra G. Buettner 2, Thomas K. Eigentler 1, Friedegund Meier 1, Benjamin Weide 1, Gisela
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationSentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Sentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationPAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma
PAPER Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma Charles R. Scoggins, MD, MBA; Adrianne L. Bowen, MD; Robert C. Martin II, MD, PhD; Michael J. Edwards, MD; Douglas
More informationCitation for published version (APA): Francken, A. B. (2007). Primary and metastatic melanoma: aspects of follow-up and staging s.n.
University of Groningen Primary and metastatic melanoma Francken, Anne Brecht IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationIncreasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma
Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma A. J. Page, Emory University A. Li, Emory University
More informationRacial differences in six major subtypes of melanoma: descriptive epidemiology
Wang et al. BMC Cancer (2016) 16:691 DOI 10.1186/s12885-016-2747-6 RESEARCH ARTICLE Racial differences in six major subtypes of melanoma: descriptive epidemiology Yu Wang 1, Yinjun Zhao 2 and Shuangge
More information6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms
6 Correlating Histology and Molecular Findings in Melanocytic Neoplasms Pedram Gerami MD, Associate Professor of Dermatology and Pediatrics at Northwestern University Disclosures: I have been a consultant
More informationIs There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma?
Is There a Benefit to Sentinel Lymph Node Biopsy in atients With T4 Melanoma? Csaba Gajdos, MD 1 ; Kent A. Griffith, MH, MS 2 ; Sandra L. Wong, MD 1 ; Timothy M. Johnson, MD 1,3 ; Alfred E. Chang, MD 1
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More informationSkin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1
Skin Cancer AMERICAN OSTEOPATHIC COLLEGE OF OCCUPATIONAL & PREVENTIVE MEDICINE OMED 2012 October 8, 2012 E. Robert Wanat II, D.O., M.P.H. Learning Objectives: Identify the 3 Basic Types of Skin Cancer
More informationPrognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk
843 Prognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk Tadashi Hasegawa, M.D. 1 Seiichiro Yamamoto, Ph.D. 2
More informationMorphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression
Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.
More informationSKIN CANCER. Most common cancer diagnosis 40% of all cancers
SKIN CANCER Most common cancer diagnosis 40% of all cancers OBJECTIVES Review common and uncommon cancers of the skin. Special emphasis on melanoma and dysplastic nevus Review pathology/tnm/staging, which
More informationPatients with thick cutaneous melanoma ( 4 mm) pose a challenge. Prognostic Factors in Patients with Thick Cutaneous Melanoma (> 4 mm)
1049 Prognostic Factors in Patients with Thick Cutaneous Melanoma (> 4 mm) Elizabeth Zettersten, M.D. 1 Richard W. Sagebiel, M.D. 1 James R. Miller III, Ph.D. 1,2 Sreedhar Tallapureddy, M.D. 1 Stanley
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationTime Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women
Time Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women Liljana Mervic 1,2 * 1 Department of Dermatology, Center of Dermatooncology, University of Tüebingen, Germany, 2
More informationMichael T. Tetzlaff MD, PhD
American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary
More informationMelanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures
More informationAn Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center
An Overview of Melanoma Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center Melanoma Statistics Median age at presentation 45-55 55 years Incidence: 2003 54,200 cases
More informationThe natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients
Annals of Oncology 28: 868 873, 2017 doi:10.1093/annonc/mdw694 Published online 30 December 2016 ORIGINAL ARTICLE The natural history and patterns of metastases from mucosal melanoma: an analysis of 706
More informationBreslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma
Research DOI: 10.6003/jtad.16104a2 Breslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma Daniela Xhemalaj, MD, Mehdi Alimehmeti, MD, Susan Oupadia, MD, Majlinda Ikonomi, MD, Leart
More informationPregnancy and Early-Stage Melanoma. BACKGROUND. Cutaneous melanomas are aggressive tumors with an unpredictable
2248 Pregnancy and Early-Stage Melanoma Deepu Daryanani, M.D. 1 John T. Plukker, M.D., Ph.D. 1 Joanne A. De Hullu, M.D., Ph.D. 2 Hilde Kuiper, M.D. 3 Raoul E. Nap, M.Sc. 1 Harald J. Hoekstra, M.D., Ph.D.
More informationWho is the Ideal Candidate for PEG Intron?
Who is the Ideal Candidate for PEG Intron? Sanjiv S. Agarwala, MD Chief, Oncology & Hematology St. Luke s Cancer Center Professor, Temple University School of Medicine Philadelphia, PA, USA Overview Introduction
More informationAdvances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision
Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate
More informationCharacteristics and Treatment of Cutaneous Melanoma of the Foot
Characteristics and Treatment of Cutaneous Melanoma of the Foot Kyung Wook Nam, Yong Chan Bae,, Soo Bong Nam, Joo Hyung Kim, Hoon Soo Kim, Young Jin Choi Department of Plastic and Reconstructive Surgery,
More informationRare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham
Rare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham Classifying melanoma Melanoma (site of origin, thickness,
More information12. Malignant Melanoma of Skin
KEY FACTS 12. Malignant Melanoma of Skin ICD-9 172 On average 160 melanomas of the skin were registered per year. Twice as common in females than in males. Higher than expected numbers in Southern Board
More informationResearch Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre
Skin Cancer Volume 2013, Article ID 904701, 7 pages http://dx.doi.org/10.1155/2013/904701 Research Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre Vera Teixeira, 1
More informationORIGINAL ARTICLE Cutaneous malignant melanoma: clinical and histopathological review of cases in a Malaysian tertiary referral centre
Malaysian J Pathol 202; (2) : 97 0 ORIGINAL ARTICLE Cutaneous malignant melanoma: clinical and histopathological review of cases in a Malaysian tertiary referral centre Jayalakshmi PAILOOR, Kein-Seong
More informationPrognostic Variables and Surgical Management of Foot Melanoma: Review of a 25-Year Institutional Experience
Virginia Commonwealth University VCU Scholars Compass Surgery Publications Dept. of Surgery 11 Prognostic Variables and Surgical Management of Foot Melanoma: Review of a 5-Year Institutional Experience
More informationPredictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma
ORIGINAL RESEARCH SURGERY // ANATOMO-PATHOLOGY Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma Călin Crăciun, Orsolya Hankó- Bauer, Zalán Benedek, Sorin Sorlea, Marius
More informationIndex. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035
Index Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, 947 948 Anorectal melanoma RT for, 1035 B Bacille Calmette-Guerin (BCG) in melanoma, 1008 BCG. See Bacille
More informationThin Melanoma. N Context. The incidence of malignant melanoma is
Thin Melanoma David E. Elder, MB ChB, FRCPA N Context. The incidence of malignant melanoma is increasing and a preponderance of the melanomas diagnosed today are thin in terms of Breslow criteria. Although
More informationUpdate on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationSENTINEL LYMPH node (SLN) biopsy has become
COMMENTARY Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement By Kelly M. McMasters, Douglas S. Reintgen, Merrick I. Ross, Jeffrey E. Gershenwald, Michael J. Edwards, Arthur
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationDesmoplastic Melanoma: Clinical Behavior and Management Implications
Desmoplastic Melanoma: Clinical Behavior and Management Implications Collier S. Pace, MD, a Jyoti P. Kapil, MD, b Luke G. Wolfe, MS, c Brian J. Kaplan, MD, c and James P. Neifeld, MD c a Division of Plastic
More informationNodal staging in localized melanoma. The experience of the Brescia Melanoma Unit
The British Association of Plastic Surgeons (2003) 56, 534 539 Nodal staging in localized melanoma. The experience of the Brescia Melanoma Unit Giorgio Manca a, *, Fabio Facchetti b, Claudio Pizzocaro
More informationORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA
ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA Benjamin E. Saltman, MD, 1 Ian Ganly, MD, 2 Snehal G. Patel, MD, 2 Daniel G. Coit, MD, 3 Mary Sue
More informationORIGINAL ARTICLE. Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection
ORIGINAL ARTICLE Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection Nir Nathansohn, MD, MHA; Jacob Schachter, MD; Haim Gutman, MD Hypothesis: Previous interventions (excisional
More information> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization
Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado
More informationSentinel Lymph Node Biopsy for the T1 (Thin) Melanoma: Is It Necessary?
Sentinel Lymph Node Biopsy for the T1 (Thin) Melanoma: Is It Necessary? Maurice Y. Nahabedian, MD Anthony P. Tufaro, MD Paul N. Manson, MD The use of sentinel lymph node biopsy for the T1 melanoma is controversial.
More informationMichael T. Tetzlaff MD, PhD
Update on American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma Emphasis on concise and accurate reporting of primary and metastatic melanoma for effective risk stratification
More informationClinical Practice Guidelines
Clinical Practice Guidelines Clinical Practice Guidelines for Melanoma Douglas Reintgen, MD, et al H. Lee Moffitt Cancer Center & Research Institute These clinical practice guidelines for melanoma have
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationM that exceeds all other solid tumors. Although education
RAPID PUBLICATION Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 By John M. Kirkwood, Myla Hunt Strawderman, Marc S.
More informationComparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure
Comparison of Melanoma Subtypes in Korean Patients Ann Dermatol Vol. 26, No. 4, 2014 http://dx.doi.org/10.5021/ad.2014.26.4.485 ORIGINAL ARTICLE Comparison of Melanoma Subtypes among Korean Patients by
More informationNodal Treatment in Melanoma: Snow to MSLT-II
Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,
More informationThe Gulf Journal of Oncology
The Gulf Journal of Oncology ISSUE 17 JANUARY 2015 Table of Contents Original Articles /Studies Impact of BMI on Locoregional Control among Saudi Patients with Breast Cancer after Breast Conserving surgery
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More information